How much funding has Airnexis Therapeutics raised?

Airnexis Therapeutics has raised $200.0M in total funding, most recently a Series A round.

Who are Airnexis Therapeutics's investors?

Airnexis Therapeutics's investors include Frazier Life Sciences, OrbiMed, SR One, Goldman Sachs Alternatives, Longitude Capital.

When was Airnexis Therapeutics founded?

Airnexis Therapeutics was founded in 2026.

Where is Airnexis Therapeutics headquartered?

Airnexis Therapeutics is headquartered in Palo Alto, California, United States.

What industry is Airnexis Therapeutics in?

Airnexis Therapeutics operates in Biotech, Healthcare.

How many employees does Airnexis Therapeutics have?

Airnexis Therapeutics has 11-50 employees.

Airnexis Therapeutics

AirNexus | AirNexis Therapeutics Launches with $200M Series A

Palo Alto, United States · Founded 2026 · $200.0M raised

Biotech

Healthcare

Headquarters: Palo Alto, California
Employees: 11–50
Founded: 2026
Business Model: B2B

Website: airnexis.com
Total Funding: $200.0M
Last Round: $200.0M Series AJan 2026
Rounds: 1

About

AirNexis Therapeutics is a clinical-stage biotech company developing novel therapeutic drugs for the treatment of COPD and pulmonary diseases. Its lead asset AN01 is a dual PDE3/4 inhibitor advancing into Phase 2 clinical trials, targeting bronchodilation and anti-inflammatory effects in COPD patients. The company launched in January 2026 with a $200M Series A led by Frazier Life Sciences.

Summary

Airnexis Therapeutics is a Biotech company based in Palo Alto, United States, founded in 2026. It has raised $200.0M in total across 1 round, most recently a $200.0M Series A round in Jan 2026. Investors include Frazier Life Sciences, OrbiMed and SR One.